The depression and the skin condition, called bullous pemphigoid ... It’s an autoimmune disease, meaning it’s a malfunction in the immune system, but there isn’t one clear cause.

Autoimmune bullous diseases are often associated with significant ... can demonstrate the presence of antibodies bound in the skin or antibodies circulating in the serum by showing specific ...

Although corticosteroids are the standard therapy for autoimmune skin diseases ... dermatosis from the various vesicular viral diseases 7. Bullous pemphigoid should be included in the differential ...

Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under ...

seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic, debilitating and relapsing skin disease. With the FDA granting a priority review status to the sBLA, a decision is ...

and the latest to be reviewed could throw a lifeline to patients with a rare and debilitating autoimmune disease affecting the skin. Bullous pemphigoid (BP), which has no FDA-approved targeted ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to ... patients achieved a 90% or greater reduction in disease severity, compared to 10% of the control ...

in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

debilitating and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin and painful lesions. “People with bullous pemphigoid ...